28 results about "CD36" patented technology

The present disclosure describes methods of specifically modulating the activity and / or number of regulatory T (Treg) cells within a tumor in a subject. Such methods may be used to reduce the number of regulatory T cells within a tumor in a subject, as well as to inhibit tumor growth in a subject with cancer without eliciting an autoimmune response. This method relies on the inhibition of CD36 or PPARbeta.

This invention discloses the application of reagents for detecting biomarker levels in the preparation of products for identifying obstructive sleep apnea. It relates to the field of biomarker technology and aims to overcome the shortcomings of existing technologies that rely on complex polysomnography (PSG) procedures, poor patient compliance, and a lack of effective molecular markers. The biomarkers used in this application consist of CD36 glycoprotein, 9-octadecenal, and protocatechuic acid 3-O-sulfate. This invention enables rapid and objective identification of obstructive sleep apnea by detecting the levels of the above biomarkers in plasma. The procedure is simple and well-accepted by patients. The combined use of multiple biomarkers can improve the accuracy and stability of the identification, making it suitable for screening or auxiliary diagnosis in medical institutions at different levels.

The present application provides siRNA and its application for specifically inhibiting CD36 gene expression. In particular, the present application provides siRNA, shRNA, recombinant vector, recombinant lentivirus, siRNA, host cell for specifically inhibiting CD36 gene expression, and its application in preparing a medicament for inhibiting CD36 gene expression / treating CD36 related diseases.

The application discloses a kind of magnetic nanoparticles for atherosclerosis diagnosis and treatment.It is core-shell structure, the inner core is Fe₃O₄ magnetic nano material, shell is the drug-loading layer of biodegradable polymer material, the drug-loading layer is encapsulated with analog movement polypeptide K271la, and the surface of nano particle is covalently coupled with CD36 targeting antibody.Its preparation method mainly includes: by complex emulsification-solvent volatilization method, Fe₃O₄ nanoparticle and K271la polypeptide are co-encapsulated in one step, form nanoparticle, and then CD36 antibody is modified on the surface of particle by chemical coupling.The nanoparticle of the application has the ability of active targeting (CD36 antibody) and passive targeting (magnetic response), can be efficiently enriched in plaque, and deliver therapeutic polypeptide to macrophages, activate lipophagy to remove lipid;It can be used as magnetic resonance imaging contrast agent, realizes diagnosis and treatment integration, and provides a new strategy for solving the problem of low efficiency of atherosclerosis targeted therapy and lack of effective monitoring means.

The present invention addresses the problem of providing: a genetically modified cultured cell or a genetically modified animal each allowing a human sapovirus to proliferate regardless of host characteristics as barriers to proliferation in mammalian cells; and an application of the cell or animal to a screening method. The present inventors have solved the problem by finding that a genetically modified cultured mammalian cell having a human CD36-encoding gene incorporated therein and a mammal having such a cell as a self-cell show acquired susceptibility to human sapovirus infection, and providing, for example, a screening method for a drug relevant to a human sapovirus on the basis of the finding.

The invention belongs to the technical field of stem cell biological medicine, and particularly relates to application of uterine blood mesenchymal stem cell outer vesicles. According to the application, external vesicles (MenSC-EVs) derived from MenSC are used as active ingredients, the MenSC-EVs effectively relieve the hepatic fibrosis condition of a mouse, the key effect of a Thbs1 / Cd36 signal on mediating intercellular communication in a fibrosis hepatic microenvironment is disclosed, and the therapeutic effect of the MenSC-EV on hepatic fibrosis and a potential molecular mechanism of the MenSC-EV are explored and confirmed.

The invention relates to the technical field of traditional Chinese medicine preparations, and discloses a salvia miltiorrhiza salvianolic acid and notoginsenoside composition, and the mass ratio of notoginsenoside to salvianolic acid in the composition is 1: 5 or 5: 3 or 3: 5. The invention further discloses application of the composition in preparation of drugs for preventing and treating vasculopathy related to metabolic syndromes of metabolic organs. The composition disclosed by the invention can be used for remarkably relieving liver lipid deposition induced by high-fat diet and reducing abnormal accumulation of white and beige fat; wherein the optimal compatibility ratio is 1: 5, and the mechanism of playing the role is related to down-regulation of the expression of liver lipid transport key protein CD36; the invention provides a new intervention strategy and compatibility basis for preventing and treating vasculopathy related to metabolic syndrome, and provides a precise intervention thought of'combining diseases and syndromes' for the research of early prevention of atherosclerosis.

The invention provides a gene marker combination and application thereof in a risk prediction model of premature eclampsia. The gene marker combination comprises a combination selected from GTF2H1, CD48, PBX1, PLA2G2A, ACVR1B, HMGB1, ERBB2, XRCC5, TGFBR2, NFKB1, EGF, TLR6, EZH2, IKZF1, EGFR and CD36, a combination of HIPK1, MTHFR, IL6R, RAB27A, UBE2I, CREBBP, SOX8, HNF4A, ICOS, LIF, TMPRSS6, DNMT3A, WWTR1, RASSF1, FOXP1, TLR2 and MAPK14, AGRN, ATP2B1, ELAC2, HDAC5, GABARAP, FXR2, NFE2L2,

The invention discloses colloidal gold chromatography test paper and a kit for detecting platelet CD36 antigen, the colloidal gold chromatography test paper comprises a bottom plate, a sample pad, a gold-labeled combination pad, a nitrocellulose membrane and a water absorption pad, the gold-labeled combination pad is coated with a colloidal gold labeled mouse anti-human CD36 IgG2a monoclonal antibody and a colloidal gold labeled quality control rabbit IgG polyclonal antibody; the nitrocellulose membrane is provided with a detection line coated with a human platelet CD36 antigen capture antibody and a quality control line coated with quality control goat anti-rabbit polyclonal antibody molecules. When the kit is used for detecting the CD36 antigen, a detected sample is fully split by the platelet lysis buffer and then is added into the sample adding hole of the kit, and a detection result can be observed after waiting for 10-15 minutes. By adopting the detection mode provided by the invention, the CD36 antigen on the human platelets can be quickly, simply, conveniently, sensitively and specifically detected.

This invention belongs to the field of biomedical materials technology and discloses a photocontrolled liquefaction hydrogel that inhibits wound scar formation, its preparation method, and its application. The photocontrolled liquefaction hydrogel is composed of the following raw materials: 6-18 parts PVA hydrogel, 3-9 parts borax-boric acid buffer solution, and 1-3 parts PDA@CeO2-SAB nanoparticle suspension. The hydrogel of this invention has the characteristics of photocontrolled liquefaction, precise drug release, inhibition of CD36 expression, good biocompatibility, and biodegradability. It can be used for infected wounds, providing a new, simple, and effective material for inhibiting wound inflammation and promoting scar repair.

The invention discloses an application of a composition of a CD36 inhibitor and a PDK4 inhibitor in preparation of a medicine for treating HFpEF, and the CD36 inhibitor and the PDK4 inhibitor are combined for use and are used for cooperatively regulating and controlling myocardial metabolism reprogramming so as to treat the HFpEF. Through combined application of the CD36 inhibitor and the PDK4 inhibitor, the effects of the combined scheme on a plurality of key indexes such as improvement of the heart diastolic function of an HFpEF mouse, improvement of exercise tolerance, reversal of cardiac hypertrophy, reduction of pulmonary congestion and myocardial fibrosis and the like are remarkably superior to those of any single-drug treatment group of SSO or DCA, and synergistic treatment is achieved.

This invention relates to a compound extracted from *Dryopteris macrocarpa*, its extraction method, and its application in the preparation of drugs for the prevention and / or treatment of non-alcoholic fatty liver disease. This invention provides a novel natural compound obtained from *Dryopteris macrocarpa* for the first time, along with a method for its preparation. Activity studies were conducted, and experimental data show that the compound exhibits low cytotoxicity to normal cells. It can inhibit fatty acid uptake in cells by suppressing the expression of fatty acid uptake-related genes FATP2 and CD36, thereby inhibiting lipid droplet accumulation and reducing cellular lipid levels. This compound can be applied in the preparation of drugs for the prevention and / or treatment of non-alcoholic fatty liver disease.

The claimed invention relates to treating cancer by targeting CD36, a fatty acid receptor. The claimed invention also relates to treating cancer metastases by targeting CD36. The invention involves using anti-CD36 antibodies as blockers or inhibitors of CD36 activity.

The present application relates to a gastric cancer diagnosis method based on gastric cancer gene targets and neural networks, comprising: obtaining gastric cancer samples and general sample data, preprocessing; and establishing a neural network model, obtaining patient gene expression data for diagnosis. The beneficial effects of the present application are: the present application establishes a neural network model based on gene targets INHBA, LYVE1, CD36 and COL10A1, and proposes a low-cost, convenient and minimally invasive method for preliminary screening of gastric cancer, so as to reduce the situation that the detection is abandoned by the detected person due to high cost, strong trauma and inconvenience of methods such as gastroscopy, resulting in delay of treatment opportunity.

The invention discloses a primer probe combination for detecting CD36 gene polymorphism and application, and relates to the field of biological gene detection. The ARMS is combined with the fluorescent PCR technology, so that the kit has the advantages of high specificity, high sensitivity, short detection time consumption, low cost and visual and easy result interpretation, and the typing of the SNP locus rs3211938 of the CD36 gene in a human whole blood sample is realized.

The application discloses a kind of biomimetic peptides derived from human beta defensin-3 and its preparation method and application.The amino acid sequence of the biomimetic peptide includes the sequence shown as SEQ ID NO.1.By the docking calculation of hBD-3 and EGFR / CD36 receptor, the key hydrogen bond binding residue and active domain are determined, and the receptor recognition function is retained by sequence connection and structure optimization.The biomimetic peptide designed in the application has biological activity, structure controllability and material compatibility, and can be widely applied to epithelial tissue repair, anti-fibrosis regulation and bio-medical material functionalization field.

The invention discloses application of a cannabidiol analogue CIAC001 in preparation of a medicine for treating non-alcoholic fatty liver disease, and belongs to the technical field of preparations of medicines containing organic active ingredients, the cannabidiol analogue CIAC001 is applied to treatment of NAFLD for the first time, it is clarified that the CIAC001 plays an anti-NAFLD role through an AMPK / PPAR gamma channel, and the application of the CIAC001 in preparation of the medicine for treating the non-alcoholic fatty liver disease in preparation of the medicine for treating the non-alcoholic fatty liver disease in preparation of the medicine for treating the non-alcoholic fatty liver disease is realized. According to the present invention, the compound can significantly reverse the decrease of the high fat diet induced AMPK phosphorylation level, inhibit the abnormally high expression of PPAR gamma, and regulate the expression of lipid metabolism related genes (Mogat1, Plin4, CD36, Cidea and Fabp5), and the clear molecular action mechanism provides the solid molecular pharmacology basis for the subsequent clinical research, dosage form development and clinical application of the compound.

The invention shows that a P. falciparum-specific interaction between a PfEMP1 adhesin and the endothelial receptor CD36 modulates sporozoite infectivity. Using a synthetic peptide to leverage this interaction, a robust high-throughput screening method has been developed to identify next-generation prophylactics against this deadly malaria parasite. The synthetic peptide is also used as a prophylactic medicament to prevent P. falciparum infection in a subject.

The invention relates to the technical field of biological medicine, and discloses a construction method and application of a CAR-M cell based on a CD36 targeting ligand gene, and an extracellular antigen binding region of the CAR-M cell comprises the CD36 targeting ligand gene; the DNA (Deoxyribose Nucleic Acid) sequence of the CD36 targeting ligand gene is as shown in SEQ ID No. 1. According to the invention, a CD36 extracellular domain structural domain is integrated into an extracellular antigen binding region of CAR as a recognition module, CAR-M cells capable of specifically targeting a PfEMP1-CD36 interaction interface can be constructed, and the addition of CD36 endows macrophages with the ability of directional recognition and iRBCs removal.

The invention belongs to the field of biological medicines, and particularly relates to application of astragaloside in preparation of a medicine for treating myocardial remodeling after myocardial infarction. In-vivo and in-vitro experiments prove that the astragaloside can up-regulate the expression of Acox1, Cd36, Pgc1a and Cpt1a lipid metabolism related factors and improve lipid metabolism disorder after myocardial infarction; meanwhile, Acta2, Col1a1, Col3a1, Postn fibrosis factors and alpha-SMA expression are inhibited, and myocardial fibrosis after myocardial infarction is relieved; the left ventricular ejection fraction and the left ventricular short axis shortening rate can be remarkably increased, the left ventricular end diastolic inner diameter and the left ventricular end systolic inner diameter are reduced, and cardiac dysfunction caused by myocardial infarction is improved. The composition can block pathological circulation of lipid metabolism disorder, myocardial fibrosis and cardiac function decline in a targeted manner, the curative effect is dose-dependent, the safety is good, and a brand new effective drug choice is provided for clinical treatment of myocardial remodeling after myocardial infarction.

The invention belongs to the technical field of medicine preparation, and particularly relates to application of hypoglycosylated apolipoprotein D in preparation of a medicine for repairing a blood brain barrier. Experiments in the invention show that in the molecular level, the binding affinity of low glycosylated apolipoprotein D (ApoD) and CD36 is increased by about 9 times compared with that of high glycosylated apolipoprotein D, and a key mechanism foundation is laid for function exertion; in an MCAO (middle cerebral artery occlusion) stroke model (middle cerebral artery occlusion model), the hypoglycosylated apolipoprotein D can remarkably repair a capillary structure, reduce an infarct area, improve neurological dysfunction, reduce blood-brain barrier permeability and enhance capillary perfusion, and the treatment efficiency is far superior to that of the hyperglycosylated apolipoprotein D; aiming at an elderly stroke model, the hypoglycosylated ApoD can improve the survival rate of mice, repair disordered and expanded capillaries, inhibit pathological endothelial cell proliferation and strengthen the integrity of a blood-brain barrier, and the hypoglycosylated ApoD can still continuously improve neurological functions and vascular phenotypes 30 days after stroke.

The present invention relates to a composition for the prevention, improvement, or treatment of obesity or obesity-induced inflammation comprising patulin as an active ingredient. A composition containing patulin as an active ingredient according to the present invention has the effect of inhibiting lipid accumulation, and can inhibit lipid accumulation by regulating sugar absorption, glycerol excretion, or LDL absorption, reducing the expression of factors related to lipogenesis or lipid synthesis such as Pparγ, Fasn, Acly, C / ebpα, Fabp4, Cd36, Dgat2, or Gpat, increasing the expression of fatty acid oxidation regulators such as PGC1α or CPT1a, and improving the volume and membrane potential of mitochondria. In addition, it can inhibit the expression of pro-inflammatory cytokines or inflammatory regulators such as IL-6, TNF-α, iNOS, or Cox-2, thereby preventing, treating, or improving obesity or obesity-induced inflammation, and can be utilized as a material for food, feed, pharmaceuticals, quasi-pharmaceuticals, etc.

The present invention provides a mass spectrometry-based method and a kit for genotyping of platelet and neutrophil antigens and glycoproteins, which are used for genotyping of platelet-specific antigens, platelet CD36 glycoproteins and neutrophil antigens; by designing an optimal primer combination, problems such as homologous sequences and rich GC are overcome, moreover, by improving amplification reaction conditions and using nucleic acid mass spectrometry as a platform, 35 platelet-specific antigen polymorphic sites, 10 CD36 polymorphic sites and 8 neutrophil antigen polymorphic sites can be simultaneously detected in 2 reactions. The present invention has the characteristics of high specificity and sensitivity, and fast and high throughput, and can be used in clinic, scientific research, platelet donor routine screening, etc.

The invention relates to the technical field of drug delivery, and discloses a macrophage-targeting SSO-loaded lipid carrier as well as a preparation method and application thereof, the lipid carrier M-SSO-L comprises liposome and sodium sulfosuccinyl oleate, and the mass ratio of the liposome to the sodium sulfosuccinyl oleate is 100: 12; the lipidosome is prepared from the following raw material components: lecithin, cholesterol and DSPE-PEG2K-mannose. The lipid carrier modified by mannose and loaded with SSO is prepared through the steps of film forming, hydration, ultrasonic treatment, extrusion, dialysis and freeze-drying, macrophages in the pancreatic cancer microenvironment can be effectively targeted, the CD36 function is inhibited, and the anti-tumor curative effect and the immune microenvironment can be remarkably improved when the lipid carrier is combined with chemotherapy.

Provided are an siRNA specifically inhibiting CD36 gene expression and the use thereof. Particularly, provided are siRNA, shRNA, a recombinant vector, a recombinant lentivirus, and a host cell that specifically inhibit CD36 gene expression, and the use thereof in the preparation of a drug for inhibiting the CD36 gene expression / treating CD36-related diseases.

The application relates to the technical field of medical data processing, in particular to a Crohn's disease prediction method based on metabolism-immunity, which comprises a collection module, a peripheral blood and a colon mucosa biopsy sample of a subject are collected to obtain data; a prediction module, a Treg cell function index is calculated according to the data, a fatty acid oxidation pathway activation index is calculated; a Crohn's risk index is calculated and a result is output; the application takes an ALA-CPT1A / CD36-FAO-Treg cell function regulation axis as a core, quantitatively couples alpha-linolenic acid concentration, expression of a core molecule of an FAO pathway, a Treg cell function comprehensive index and a clinical correction factor, and sequentially constructs: a Treg cell function comprehensive index reflecting an immune core state; an FAO pathway synergistic activation index reflecting a regulation effect of metabolism on immunity; and prediction is realized in combination with the Treg cell function comprehensive index, the FAO index and clinical correction.

This invention discloses the application of ZFP36 as a target in anti-non-small cell lung cancer (NSCLC) drugs and pharmaceutical compositions, belonging to the field of biomedical technology. The invention upregulates ZFP36 expression or enhances its RNA-binding activity, utilizing the zinc finger domain composed of amino acids 115-148 of the ZFP36 protein to specifically bind to the ATTTA-type ARE motif of the FASN mRNA 3'UTR and promote target mRNA degradation, thereby downregulating the expression of FASN, lipid droplet-related proteins, and CD36, thus triple-inhibiting lipid droplet metabolism. Simultaneously, it inhibits CAF secretion of lipid carriers, blocking lipid transport and metabolic remodeling in the tumor microenvironment. This invention can inhibit NSCLC cell proliferation, induce apoptosis, and reverse chemotherapy resistance. It clarifies that ZFP36-related biomarkers can be used for lung cancer chemotherapy resistance subtyping and targeted efficacy prediction, providing a novel target and approach for precision treatment of NSCLC, and possessing excellent clinical translational value.

The invention discloses a biomimetic peptide derived from human beta defensin-3 as well as a preparation method and application of the biomimetic peptide. The amino acid sequence of the biomimetic peptide comprises a sequence as shown in SEQ ID NO. 1. According to the present invention, through the docking calculation of the hBD-3 and the EGFR / CD36 receptor, the key hydrogen bond binding residue and the active structure domain are determined, and the receptor recognition function is retained through the sequence connection and the structure optimization; the bionic peptide designed by the invention has biological activity, structural controllability and material compatibility, and can be widely applied to the fields of epithelial tissue repair, anti-fibrosis regulation and control and biomedical material functionalization.